Circulating donor-specific anti-human leukocyte antigen antibodies and complement c4d deposition are associated with the development of cardiac allograft vasculopathy

American Journal of Clinical Pathology

Volumn 142, Issue 6, 2014, Pages 809-815

  Frank, Renee ^a   Molina, Maria R ^b   Goldberg, Lee R ^b   Wald, Joyce W ^b   Kamoun, Malek ^a   Lal, Priti ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute antibody mediated rejection; C4D; Cardiac allograft vasculopathy; Donor specific antibodies

Indexed keywords

BASILIXIMAB; COMPLEMENT COMPONENT C4D; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA C ANTIGEN; HLA DPB1 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; RITUXIMAB; TACROLIMUS; ANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; HLA ANTIGEN; PEPTIDE FRAGMENT;

ADULT; AGED; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONFERENCE PAPER; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART GRAFT; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY; PLASMAPHERESIS; PRIORITY JOURNAL; PUVA; ALLOGRAFT; DONOR; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLOGRAFTS; ANTIBODIES; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; TISSUE DONORS; YOUNG ADULT;

EID: 84922278961     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPTLBEU5BQ8SHN     Document Type: Conference Paper

References (30)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult heart transplant report-2010. J Heart Lung Transplant. 2010;29:1089-1103.
2. Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant. 2011;25:175-184.
3. Braga JR, Santos IS, McDonald M, et al. Factors associated with the development of cardiac allograft vasculopathy-a systematic review of observational studies. Clin Transplant. 2012;26:E111-E124.
4. Uber WE, Self SE, Van Bakel AB, et al. Acute antibody-mediated rejection following heart transplantation. Am J Transplant. 2007;7:2064-2074.
5. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7:408-415.
6. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30:601-611.
7. Roussel JC, Baron O, Perigaud C, et al. Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality. J Heart Lung Transplant. 2008;27:486-493.
8. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17:744-753.
9. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717-727.
10. Chen W, Thoburn CJ, Miura Y, et al. Autoimmune-mediated vasculopathy. Clin Immunol. 2001;100:57-70.
11. de Denus S, Al-Jazairi A, Loh E, et al. Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients. Ann Pharmacother. 2004;38:1136-1141.
12. Kahn J, Rehak P, Schweiger M, et al. The impact of overweight on the development of diabetes after heart transplantation. Clin Transplant. 2006;20:62-66.
13. McDonald K, Rector TS, Braulin EA, et al. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359-362.
14. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-1720.
15. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32:1147-1162.
16. Moseley EL, Atkinson C, Sharples LD, et al. Deposition of C4d and C3d in cardiac transplants: A factor in the development of coronary artery vasculopathy. J Heart Lung Transplant. 2010;29:417-423.
17. Stoica SC, Cafferty F, Pauriah M, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006;25:420-425.
18. Lee MS, Finch W, Weisz G, et al. Cardiac allograft vasculopathy. Rev Cardiovasc Med. 2011;12:143-152.
19. Tavora F, Munivenkatappa R, Papadimitriou J, et al. Endothelitis in cardiac allograft biopsy specimens: possible relationship to antibody-mediated rejection. J Heart Lung Transplant. 2011;30:435-444.
20. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant. 2012;12:313-321.
21. Kfoury AG, Renlund DG, Snow GL, et al. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant. 2009;28:51-57.
22. Loupy A, Cazes A, Guillemain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant. 2011;11:1478-1487.
23. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28:417-422.
24. Frank R, Molina MR, Wald JW, et al. Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: A single-center, retrospective study. J Heart Lung Transplant. 2013;32:410-417.
25. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033-1041.
26. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11:312-319.
27. Baldwin WM, Kasper EK, Zachary AA, et al. Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant. 2004;4:311-318.
28. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol. 2005;5:807-817.
29. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation. 2010;90:1473-1477.
30. Reinsmoen NL, Lai CH, Mirocha J, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation. 2014;97:595-601.